An alternative to metformin may be appropriate when the drug causes intolerable side effects, when kidney function declines below safe thresholds, or when another medication better matches goals like weight loss or cardiovascular risk reduction. The main alternatives include SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, sulfonylureas, thiazolidinediones, and structured lifestyle therapy. Each has a different A1C effect, weight profile, hypoglycemia risk, and cost — no single drug is best for everyone.
Why People Look for Alternatives to Metformin
Metformin has been the most prescribed first-line drug for type 2 diabetes for more than 60 years. It is inexpensive (often under 4 dollars per month), reduces A1C by about 1.0 to 1.5 percent, does not cause hypoglycemia on its own, and may have long-term protective effects on cardiovascular events and cancer risk based on long-running trials like the UK Prospective Diabetes Study. Yet roughly 20 to 30 percent of users develop gastrointestinal side effects — diarrhea, nausea, abdominal cramps, metallic taste — that range from mild to disabling.
Common reasons clinicians consider alternatives include:
- Persistent GI intolerance not resolved by the extended-release formulation or food-with-dosing strategies
- Declining kidney function (eGFR below 30 mL/min/1.73m2)
- Vitamin B12 deficiency that develops after several years of use
- A1C remaining above goal despite maximum metformin (typically 2,000 mg per day)
- Coexisting heart failure, atherosclerotic cardiovascular disease, or chronic kidney disease — where SGLT2 inhibitors and GLP-1 agonists offer added organ protection
- Obesity where weight loss is a primary goal — GLP-1 receptor agonists generally produce more weight loss than metformin
- Patient preference or pill burden concerns
Drug Classes That Can Replace or Add to Metformin
| Class | Examples | A1C Reduction | Weight Effect | Hypoglycemia Risk | Typical Monthly Cost (US) |
|---|---|---|---|---|---|
| Biguanide (metformin) | Metformin IR, ER | 1.0–1.5% | Neutral / mild loss | Very low | $4–$20 |
| SGLT2 inhibitors | Empagliflozin, dapagliflozin, canagliflozin | 0.7–1.0% | Loss (2–3 kg) | Low | $500–$650 |
| GLP-1 receptor agonists | Semaglutide, dulaglutide, liraglutide | 1.0–1.8% | Loss (3–6 kg or more) | Low | $900–$1,200 |
| DPP-4 inhibitors | Sitagliptin, linagliptin, saxagliptin | 0.5–0.8% | Neutral | Low | $400–$550 |
| Sulfonylureas | Glipizide, glimepiride, glyburide | 1.0–1.5% | Gain (2–3 kg) | Moderate to high | $4–$15 |
| Thiazolidinediones | Pioglitazone | 0.8–1.4% | Gain (2–4 kg) | Low | $10–$40 |
| Alpha-glucosidase inhibitors | Acarbose, miglitol | 0.5–0.8% | Neutral | Low | $50–$120 |
| Insulin | Glargine, detemir, NPH, others | Variable — can reduce any A1C | Gain | High | $25–$300+ |
SGLT2 Inhibitors — A Common Modern First Choice
SGLT2 inhibitors block glucose reabsorption in the kidney, causing excess glucose to leave the body in urine. They modestly lower A1C, produce small but consistent weight loss, lower blood pressure, and have shown major benefits in cardiovascular and kidney outcomes trials. Empagliflozin and dapagliflozin are approved for heart failure with reduced ejection fraction regardless of diabetes status, and both have approvals for chronic kidney disease.
Notable considerations:
- Increased risk of genital yeast infections (3 to 6 times baseline) — especially in women and uncircumcised men
- Mild increase in urinary tract infection rate
- Volume depletion — caution in older adults and those on diuretics
- Rare risk of euglycemic diabetic ketoacidosis — particularly during fasting, surgery, or low-carbohydrate diets
- Effectiveness declines as kidney function declines (different cutoffs for each agent)
GLP-1 Receptor Agonists — When Weight Loss and CV Protection Matter
GLP-1 receptor agonists mimic the natural incretin hormone glucagon-like peptide-1. They enhance glucose-dependent insulin release, slow gastric emptying, reduce glucagon secretion, and act on appetite centers in the brain. Most are weekly subcutaneous injections (semaglutide, dulaglutide); some are daily (liraglutide); oral semaglutide (Rybelsus) is a daily tablet.
This class produces the largest A1C reduction and the most weight loss among non-insulin diabetes drugs. The REWIND trial showed dulaglutide reduced major adverse cardiovascular events in people with type 2 diabetes, with or without prior cardiovascular disease. Semaglutide and liraglutide have similar outcomes data.
Common drawbacks: nausea, diarrhea, and constipation are frequent during dose escalation. Cost is high without insurance. Personal or family history of medullary thyroid carcinoma or MEN2 syndrome is a contraindication.
DPP-4 Inhibitors — Easy Tolerability, Smaller Effect
DPP-4 inhibitors prolong the action of natural incretins (rather than supplying a synthetic one as GLP-1 agonists do). They are well tolerated, weight-neutral, do not cause hypoglycemia on their own, and come as once-daily pills. The trade-off is a smaller A1C effect — typically 0.5 to 0.8 percent.
Linagliptin is notable for not requiring dose adjustment in kidney disease. Saxagliptin has been associated with a small increase in heart failure hospitalization in one trial (SAVOR-TIMI 53). Joint pain has been reported in rare cases.
Sulfonylureas — Effective but with Trade-offs
Sulfonylureas (glipizide, glimepiride, glyburide) stimulate insulin release from beta cells regardless of current glucose level. They are highly effective at lowering A1C, inexpensive, and have decades of clinical experience. However:
- Risk of hypoglycemia is higher than any other oral class — particularly with skipped meals, exercise, or alcohol
- Weight gain of 2 to 3 kg is common
- Beta-cell effects tend to wane after several years (secondary failure)
- Glyburide has the highest hypoglycemia risk and is generally avoided in older adults
Thiazolidinediones — Insulin Sensitizers
Pioglitazone improves insulin sensitivity at the cellular level. It lowers A1C effectively, has a favorable effect on triglycerides, and has shown reductions in stroke and recurrent cardiovascular events in some populations. Concerns include weight gain, fluid retention (contraindicated in heart failure), increased fracture risk in postmenopausal women, and a debated small bladder cancer signal. It is rarely used as first-line today.
Lifestyle Therapy — Sometimes the Strongest Alternative
For people with prediabetes or early type 2 diabetes, structured lifestyle change can be more effective than any single drug. The Diabetes Prevention Program showed that a 7 percent weight loss plus 150 minutes per week of moderate activity reduced progression to diabetes by 58 percent — significantly more than metformin’s 31 percent reduction in the same trial.
Practical elements:
- Mediterranean or DASH eating patterns — emphasizing vegetables, legumes, fish, nuts, olive oil, and whole grains
- Reducing refined carbohydrates and sugary drinks
- Daily walking, strength training 2 days per week, and limiting prolonged sitting
- Sleep regularization (7 to 9 hours) and stress reduction
- Tobacco cessation
See our diet and nutrition guide and whether prediabetes is reversible for more detail.
Matching the Alternative to the Person
| Patient Situation | Reasonable First Alternative |
|---|---|
| GI intolerance on immediate-release metformin | Switch to ER formulation; if still intolerant, DPP-4 inhibitor or GLP-1 agonist |
| eGFR less than 30 mL/min/1.73m2 | Linagliptin, GLP-1 agonist, SGLT2 inhibitor (if eGFR allows), insulin |
| Heart failure | SGLT2 inhibitor (empagliflozin or dapagliflozin) |
| Atherosclerotic cardiovascular disease | GLP-1 agonist or SGLT2 inhibitor with proven CV benefit |
| Obesity (BMI 30+) | GLP-1 receptor agonist (semaglutide, dulaglutide, liraglutide) |
| Cost is the main barrier | Sulfonylurea (glipizide) plus structured lifestyle program |
| Early prediabetes, mild A1C elevation | Structured lifestyle therapy without medication |
Berberine and Other Supplements
Berberine is the supplement most often discussed as a metformin-like alternative. It activates AMPK (one of metformin’s molecular targets) and has shown modest A1C reductions of about 0.7 to 1.0 percent in small studies. Limitations: supplement quality varies, GI side effects can be similar to metformin, and meaningful drug interactions exist with antibiotics, anticoagulants, immunosuppressants, and statins. It is not FDA-approved for diabetes treatment. Other supplements (cinnamon, alpha-lipoic acid, chromium) have weaker evidence and should not replace prescribed therapy without medical advice.
Combining Alternatives
When one drug alone is not enough, combinations are common. Metformin plus a GLP-1 agonist plus an SGLT2 inhibitor is a frequent modern combination for people with A1C above goal, obesity, and cardiovascular risk. The American Diabetes Association’s Standards of Care 2024 prioritizes choosing additional drugs based on comorbidities — cardiovascular, kidney, heart failure, and weight — rather than purely by A1C effect.
Discussing the Switch with Your Clinician
Useful questions to bring to the appointment:
- Have we tried extended-release metformin to address GI side effects?
- What is my current eGFR and how does that change my options?
- Do I have cardiovascular disease, heart failure, or kidney disease that would change drug priority?
- What weight goal are we aiming for, and which drug class supports that?
- What does my insurance cover, and is there a manufacturer copay card?
- How will we monitor whether the new drug is working — what A1C target and what timeline?
For background on A1C targets, see our A1C levels guide.
The Bottom Line
There is no single best alternative to metformin — the right choice depends on why metformin is being replaced, what other conditions are present, and what goals matter most. SGLT2 inhibitors and GLP-1 receptor agonists are increasingly preferred when cardiovascular disease, heart failure, kidney disease, or obesity are part of the picture. DPP-4 inhibitors are easy-to-tolerate weaker options. Sulfonylureas remain cheap and effective but carry hypoglycemia risk. Structured lifestyle therapy can match medication in early disease. Any change should be discussed with the prescribing clinician, with a plan for follow-up A1C testing and side-effect monitoring within 3 months of switching.
